Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|June 6, 2024
Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environmentsMarine Baron, Karim Labreche, Marianne Veyri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 OligodendrogliomaSalah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, et al.
Genome Biology|August 6, 2024
Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiationVincent Jonchère, Hugo Montémont, Enora Le Scanf, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Neuro-Oncology|August 19, 2025
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future DirectionsPatrick Y Wen, Michael Weller, Eudocia Q Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|June 6, 2024
Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environmentsMarine Baron, Karim Labreche, Marianne Veyri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 OligodendrogliomaSalah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, et al.
Genome Biology|August 6, 2024
Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiationVincent Jonchère, Hugo Montémont, Enora Le Scanf, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Neuro-Oncology|August 19, 2025
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future DirectionsPatrick Y Wen, Michael Weller, Eudocia Q Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Pageof 10